KPV (10 mg Vial) Dosage Protocol
KPV is the C-terminal tripeptide (Lys-Pro-Val) of α-MSH. It retains the anti-inflammatory and antimicrobial properties of α-MSH without the pigmentation effects.
⚡ Quickstart Highlights
Dosing & Reconstitution Guide
Route: Subcutaneous (oral capsule for GI protocols) | Frequency: Once or twice daily | Half-life: ~30 minutes
Standard Approach (3 mL = 3.33 mg/mL)
Reconstituting with 3 mL bacteriostatic water produces a concentration of 3.33 mg/mL. Volume per dose changes with concentration; mg dose itself does not change between vial sizes.
| Phase / Protocol | Dose | U-100 Units | Volume | Doses per vial |
|---|---|---|---|---|
| Week 1 (titration) | 200 mcg | 6 units | 0.060 mL | 50 doses |
| Week 2 | 300 mcg | 9 units | 0.090 mL | 33 doses |
| Week 3 | 400 mcg | 12 units | 0.12 mL | 25 doses |
| Weeks 4–8 (target) | 500 mcg | 15 units | 0.15 mL | 20 doses |
Reconstitution Steps
- Wipe the vial stopper and BAC water vial with alcohol; let dry.
- Draw 3 mL of bacteriostatic water into a sterile syringe.
- Inject slowly down the inside glass wall of the peptide vial. Do not aim at the powder.
- Gently swirl until fully dissolved. Do not shake.
- Label with reconstitution date. Refrigerate at 2–8°C; use within 30 days.
Supplies Needed
Estimates for an 8-week and 12-week cycle at 400 mcg per dose, once or twice daily (14 doses/week).
| Item | 8-Week Cycle | 12-Week Cycle |
|---|---|---|
| KPV (10 mg) vials | 5 vials | 7 vials |
| Insulin syringes (U-100) | 112 | 168 |
| Bacteriostatic water (10 mL) | 2 × 10 mL | 3 × 10 mL |
| Alcohol swabs | 1 × 100-pack | 2 × 100-pack |
Protocol Overview
KPV protocols vary significantly by indication — gut-focused (IBD, ulcerative colitis) protocols use higher doses with oral capsules added; systemic anti-inflammatory protocols use sub-Q daily; skin protocols often use topical alongside sub-Q.
Dosing Protocol
Dosing by intensity:
- Light (250 mcg/day): Daily anti-inflammatory maintenance.
- Standard (500 mcg/day): Most-cited research dose.
- Higher (1 mg/day): IBD or acute inflammation protocols.
Oral protocol: 500 mcg–1 mg twice daily oral capsule for direct gut exposure in IBD research.
Cycle: 8–12 weeks active dosing, then reassess. Continuous use is acceptable given safety profile.
Stacking: Commonly added to BPC-157 in gut-mucosa protocols.
Storage Instructions
| State | Temperature | Duration |
|---|---|---|
| Lyophilized | −20°C (−4°F) | Up to 24 months, dry & dark |
| Reconstituted | 2–8°C (35–46°F) | Up to 30 days, protect from light |
Important Notes
How This Works
KPV is the active C-terminal tripeptide of alpha-melanocyte-stimulating hormone (α-MSH). It retains the potent anti-inflammatory activity of α-MSH but lacks the melanocortin pigmentation effects.
It downregulates NF-κB and pro-inflammatory cytokines (TNF-α, IL-6), modulates immune cell trafficking, and exhibits direct antimicrobial activity against bacteria, fungi, and yeasts. Studied in inflammatory bowel disease, atopic dermatitis, and acute inflammation.
Potential Benefits & Side Effects
Potential Benefits
- Anti-inflammatory effects across multiple tissue types.
- IBD model improvements via NF-κB downregulation.
- Antimicrobial activity (broad-spectrum).
- Skin condition improvements in atopic dermatitis models.
- Pairs well with BPC-157 for gut-mucosal protocols.
Side Effect Profile
- Generally well-tolerated.
- Mild injection-site reactions possible.
Lifestyle Factors
- Adequate hydration and electrolytes during gut-focused protocols.
- Anti-inflammatory diet (omega-3, low refined sugar) complements effects.
- Sleep adequacy supports immune regulation.
Injection Technique
- Subcutaneous into abdomen, thigh, or upper arm. Rotate sites.
- Some IBD protocols use oral capsule formulations for direct gut exposure.